Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause 1-3
Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world 4-6
IL-31 is a neuroimmune cytokine that is involved in inflammation and fibrosis – both hallmarks of SSc – and drives itch, a key symptom of CPUO 1,3,4
Enrollment for Galderma's phase II studies of nemolizumab is planned to begin in H2 2025
Article content
ZUG, Switzerland — Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need. 1-3,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc. 1,3,4
'Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these severe and potentially life-threatening conditions.'
BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.
GLOBAL HEAD OF R&D
GALDERMA
Systemic Sclerosis (SSc) SSc is a rare, potentially fatal autoimmune disease that causes inflammation and fibrosis (hardening) of the skin and internal organs. 1 It most commonly affects women between the ages of 30 and 50 years old, often leading to a lower quality of life and a much higher risk of death compared to healthy people of the same age. 2,8 Currently, there are no approved therapies that address the disease as a whole, highlighting the urgent need for effective treatments. 1,2,8 Galderma's phase II proof-of-concept study is a multicenter, randomized, double-blind, placebo-controlled study investigating the pharmacokinetics and pharmacodynamics of nemolizumab in adults with SSc. Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028. This trial represents a significant step towards addressing the remaining unmet treatment needs in SSc and demonstrates Galderma's commitment to driving progress for patients living with this disease.
Article content
Article content
The study was designed in collaboration with a Steering Committee of world-leading rheumatology and dermatology experts, including lead trial investigator, Professor Oliver Distler, M.D., Zürich, Switzerland; Professor Dinesh Khanna, M.D., Director of the Scleroderma Program, University of Michigan, United States (U.S.); Professor Robert Spiera, M.D., Director of the Scleroderma, Vasculitis and Myositis Center, Hospital for Special Surgery, New York, U.S.; and Professor Johann Gudjonsson, M.D., PhD, Dermatologist, University Hospital Michigan, U.S.
Article content
The trial is expected to be conducted in several countries in North America, Europe and South America. More information about the study will be made available soon on the clinicaltrials.gov website.
Article content
CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause and mostly affects the elderly. 3 The chronic and persistent itch is often described as being as debilitating as chronic pain, leading to reduced quality of life and affecting sleep patterns and mood. 3,7 There are currently no approved treatments for this condition. 3 Galderma's new phase II CPUO trial reinforces the company's commitment to exploring options for patients with chronic skin conditions that significantly impact quality of life. This randomized, double-blind, placebo-controlled proof-of-concept study will explore the pharmacokinetics and pharmacodynamics of nemolizumab in adults. Enrollment is expected to start in H2 2025 in the U.S., with completion anticipated in 2026. The study was designed in collaboration with a Steering Committee of world-leading dermatology experts, including the lead investigator Dr. Shawn Kwatra, M.D., PhD., Joseph W. Burnett Endowed Professor, Chairman of Dermatology, University of Maryland School of Medicine, U.S., and Dr. Sarina Elmariah, MD, PhD, MPH, Associate Professor and Dermatology Director at the Center for Itch and Neurosensory Disorders at the University of California in San Francisco, U.S.
Article content
The study is being conducted in the U.S. and more information about the study will be made available soon on the clinicaltrials.gov website.
Article content
Nemolizumab was approved in August 2024 by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis. 5 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. 5 To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the European Union, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing.
Article content
Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga ® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients. 9,10 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
Article content
References
1.
Jimenez SA, Mendoza FA, Piera-Velasquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol. 2025;16: 1551911. doi: 10.3389/fimmu.2025.1551911
2.
Truchetet ME, et al. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol. 2021;64(3): 262–283. doi: 10.1007/s12016-021-08889-8
3.
Teresa J, et al. Therapeutics in chronic pruritus of unknown origin. Itch. 2023;8(1): pe64. doi: 10.1097/itx.0000000000000064
4.
Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1): 173-182. doi: 10.1016/j.jaci.2019.08.013
5.
Nemluvio ® U.S. Prescribing Information. Available online. Accessed June 2025
6.
Nemluvio ® European Medicines Agency. Summary of Product Characteristics. Available online. Accessed June 2025
7.
Andrade E, et al. Interventions for chronic pruritus of unknown origin. CDSR. 2020;1(1): CD013128. doi: 10.1002/14651858.CD013128.pub2
8.
Scleroderma & Systemic Sclerosis. National Health Service. Available online. Accessed June 2025
9.
Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed June 2025
10.
Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed June 2025
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
For further information:
Article content
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Article content
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Article content
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Article content
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
13 hours ago
- CTV News
Why more women are switching to reusable menstrual products
A pharmacist prepares an underwear for periods next to other items at a pharmacy in Barcelona, Spain, March 5, 2024. (AP Photo/Emilio Morenatti, File) It was six months ago that Selin Celikoyar bought her last tampon and switched to a reusable menstrual disc. 'I had already been wary of tampons from an environmental perspective and also from a biological perspective. I felt that they were very wasteful and expensive to consistently keep buying,' she said. The flexible discs and other reusable menstrual products are gaining traction as alternatives to the billions of single-use pads and tampons that get tossed into landfills every year. Products such as the discs, silicone cups and period underwear can be reused for years, so they're cost-effective and long-lasting in addition to helping people reduce waste. The popularity of the reusable alternatives has grown since the pandemic, when it was easier to experiment with period products in the privacy of a home bathroom, according to women's health experts. Celikoyar said she used tampons and pads for years because those are the options she grew up knowing about. But when she saw her friend make the switch to a menstrual disc, she decided to try it too. 'The experience has been such a game changer,' she said. Single-use products wind up in landfills About 12 billion disposable pads and 7 billion tampons go into U.S. landfills every year, according to Dr. Luwam Semere, chief of obstetrics and gynecology at Kaiser Permanente Santa Clara. Pads are mostly plastic. Once they're in the landfill, they take up to 800 years to degrade, according to the National Institutes of Health. Single-use pads and tampons are by far the most popular period products. Women's health expert Dr. Navya Mysore said that's not because they're better, they're just usually the first options kids are shown. 'It was often like, 'What did your mom use? What did your grandma use?' And that's how you were introduced into period hygiene,' said Mysore, a primary care physician based in New York City. Advantages and drawbacks to switching The most popular is the menstrual cup, which gets inserted much like a tampon. The discs get inserted farther in, so they don't interrupt intercourse. Both can hold several times more than a tampon and can stay inserted for up to 12 hours, instead of the four to eight hours recommended for tampons. Semere also said the risk of Toxic Shock Syndrome commonly associated with tampons is much lower with menstrual cups and discs. The cons? The products require some technique to put them in right, and doing it wrong can get messy. The cups and discs also have to be cleaned regularly with soap and water. 'It's hard to do that if you're at work and you're in a shared, public restroom. It's not the most convenient,' said Mysore. Cups prevent leakage by creating a suction, so people who use intrauterine devices for contraception risk dislodging them if they pull out a menstrual cup without breaking the seal. The placement of discs, which don't use suction, can also take some getting used to. 'It's high up there, you don't feel it, but it can be sometimes harder for women to pull them out,' said Dr. Annemieke van Eijk, an epidemiologist with the Liverpool School of Tropical Medicine. But for Celikoyar, the advantages of the discs outweighed the drawbacks. She said that longer changing window has gotten her through a back-to-back concert and red-eye flight without any concern. 'There's an ease of use there for the modern woman that is significantly better than traditional methods,' she said. Comparing costs Menstrual cups and discs typically cost between US$15 and $40 and come in different shapes and sizes. They're available online and at pharmacies and big box stores. 'Ideally, you would like to experiment a bit with what type of cup works best for you. And the cost can be kind of prohibitive to do that,' van Eijk said. A reusable product can help save money over the long term. Celikoyar estimates that she was using three tampons every day for seven days, or about 20 per month. With tampons costing 20 to 25 cents each, someone who switched to a reusable product would likely break even after a few months. For people who prefer pads, the most common reusable option is period underwear, which is comparable to regular-looking underwear with an extra absorbent lining. 'Those are nice because we do see people getting irritation from pad use,' said Semere. 'Because of the different materials that are in the disposable pads.' The downside, just like with pads, is the inability to tell when it's absorbed all that it can. Mysore said that's why some of her patients use the underwear as a backup, and pair them cups, discs or tampons. 'You can sort of mix and match different period products, depending on how heavy your flow is and what your period is like for you,' she said. ___ Caleigh Wells, The Associated Press The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at
Globe and Mail
16 hours ago
- Globe and Mail
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
Agenus Inc. ('Agenus' or the 'Company') (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) immunotherapy combination. Botensilimab is a next-generation, multifunctional, Fc enhanced, CTLA-4 antibody and BAL is a proprietary PD-1 antibody; together they are designed to trigger robust and durable immune attacks against 'cold,' treatment-resistant tumors, offering new hope where standard therapies have failed. 'Our team is committed to advancing BOT/BAL to deliver meaningful benefits to patients with treatment-resistant cancers, and we are working with regulatory agencies to expedite access through a streamlined Phase 3 trial,' said Garo Armen, Ph.D., Chairman and Chief Executive Officer of Agenus. 'With significant clinical progress, strategic partnerships, and prudent financial management, we are well-positioned to execute our vision of transforming cancer care.' Regulatory Highlights Breakthrough Survival in Refractory MSS CRC – At the 2025 ESMO Gastrointestinal Cancers Congress, BOT + BAL reported a 42% two-year survival rate and median overall survival of ~21 months in a trial of 123 patients with refractory no liver met MSS metastatic colorectal cancer (mCRC). Regulatory Alignment on Registrational Phase 3 Trial (BATTMAN) – Following an End-of-Phase 2 meeting on July 1, 2025, the FDA agreed to a streamlined two-arm BATTMAN Phase 3 design, having agreed to BOT/BAL's contribution of components. This agreement also marks a shift from a three-arm trial previously proposed by regulators and enables trial initiation in Q4 2025. Expanding Evidence Across Tumor Types – New data from a neoadjuvant pan-cancer trial (NEOASIS study) showed robust pathological responses across MSS and MSI-H solid tumors, including triple-negative breast cancer, with no dose-limiting toxicities. Translational data from ASCO confirmed BOT/BAL's ability to activate T cells and address resistance in MSS tumors, supporting its potential across cancers. 'The BOT/BAL combination is delivering durable responses and survival outcomes in refractory MSS colorectal cancer,' said Richard M. Goldberg, M.D., Chief Development Officer of Agenus. 'With regulatory clarity and a focused development team, we are poised to execute the BATTMAN trial and explore earlier treatment settings to maximize patient impact.' Strategic Partnerships Zydus Lifesciences Collaboration – The collaboration for U.S. manufacturing and commercialization in India/Sri Lanka is progressing toward a Q3 2025 closing, delivering $91M in upfront capital and equity investment upon closing to support development and regulatory activities. Noetik AI Biomarker Collaboration using AI algorithms – Agenus commenced a partnership with Noetik AI to refine patient selection, enhancing BOT/BAL's clinical impact and unlocking potential future revenue streams through precision oncology. Broader Portfolio Synergies – Agenus continues to leverage its significant ownership of MiNK Therapeutics and SaponiQx, to advance combination treatments with adoptive cell therapies and adjuvants, broadening its immuno-oncology pipeline. Key 2H 2025 Catalysts— Building on recent clinical, regulatory, and partnership momentum, Agenus anticipates several significant milestones in the second half of 2025: Registrational Trial Launch – In Q4 2025, initiate the global BATTMAN Phase 3 trial of BOT/BAL in refractory MSS CRC in partnership with the Canadian Clinical Trials Group (CCTG), committed to executing with speed and precision. Significant Clinical Data Generation – Expand evidence for BOT/BAL's activity in earlier-line and neoadjuvant MSS colorectal cancer and other tumors through strategic collaborations and investigator-sponsored trials. Upcoming Data Presentations – Share new BOT/BAL clinical results in colorectal and other solid tumors at major oncology congresses in Q4 2025, reinforcing its therapeutic potential. Financial Highlights— Agenus continues to strengthen its financial position through prudent cost management and strategic capital-raising efforts in addition to Zydus collaboration, positioning the company to execute its clinical and regulatory objectives. Key financial metrics for Q2 2025 are summarized below: Financial Highlights (in thousands, except per share data) (unaudited) Key Financial Metrics Q2 2025 Q2 YTD 2025 Q2 YTD 2024 Revenue, including non-cash royalties $ 25.7 $ 49.8 $ 51.5 Net loss 30.0 56.4 118.3 Net loss per share attributable to Agenus Inc. common stockholders 1.00 2.03 5.56 Cash used in operations 20.2 45.8 76.4 Cash and cash equivalents June 30, 2025 $ 9.5 Post Q2 capital raised $ 5.2 Cash expected Q3 2025 from Zydus transactions $ 91.0 Revenue and Net Loss – Agenus reported revenue of $25.7 million for Q2 2025 and $49.8 million for Q2 YTD 2025, primarily from non-cash royalty revenue, compared to $51.5 million in Q2 YTD 2024. The net loss Q2 YTD 2025 was $56.4 million, or $2.03 per share, a significant improvement from $118.3 million, or $5.56 per share, for Q2 YTD 2024. Reduced Cash Burn – Cash used in operations decreased to $45.8 million for Q2 YTD 2025 from $76.4 million for Q2 YTD 2024. These reductions are a consequence of prudent cost management and are expected to continue into the second half of 2025. Agenus is also in active negotiations for collaborations that could result in additional significant infusions of cash resources. Liquidity and Future Outlook – With the $91 million Zydus infusion expected upon closing, combined with its current cash balance, Agenus expects to fund the launch of its Phase 3 trial. Further, the company is in negotiations to secure additional funding streams from partnerships currently under negotiation and BOT/BAL's commercial prospects in geographies beyond North America, Europe and Japan. Webcast and Conference Call Information The Company will host a webcast and Stakeholder Briefing on August 27, 2025, to review Q2 financial results, anticipated data milestones, and the global BOT/BAL development program. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. Founded in 1994, Agenus is advancing antibody therapeutics, adoptive cell therapies through MiNK Therapeutics, and adjuvants through SaponiQx, leveraging robust end-to-end development capabilities, including commercial and clinical cGMP manufacturing facilities and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Agenus' Commitment to Patient Access Agenus is dedicated to making investigational medicines available to patients with cancer at the appropriate time and in the correct manner. For more information, visit About Botensilimab (BOT) Botensilimab (AGEN1181) is a next-generation, multifunctional, Fc-enhanced CTLA-4 antibody engineered to boost both innate and adaptive anti-tumor immune responses. Its unique design aims to overcome the limitations of first-generation CTLA-4 inhibitors (like ipilimumab) and extend immunotherapy benefits to 'cold' tumors that typically respond poorly or not at all to standard immune checkpoint blockade. Botensilimab's Fc-enhanced structure allows it to robustly engage activating Fc receptors on key immune cells, thereby priming and activating T cells, depleting immunosuppressive regulatory T cells in the tumor microenvironment, activating myeloid cells, and inducing long-term immune memory. Through these mechanisms, botensilimab has demonstrated the ability to ignite immune responses across a range of solid tumors, including those resistant to conventional PD-1 or CTLA-4 therapies. To date, approximately 1,200 patients have been treated with botensilimab and/or balstilimab in Phase 1 and 2 trials. Botensilimab alone or in combination with Agenus' investigational PD-1 antibody balstilimab has shown clinical responses in nine different metastatic cancers in late-line settings. For more information on ongoing botensilimab trials, please visit About Balstilimab (BAL) Balstilimab (AGEN2034) is a novel, fully human monoclonal IgG4 antibody that blocks PD-1 (programmed cell death-1) from interacting with its ligands PD-L1 and PD-L2. By inhibiting the PD-1 checkpoint pathway, balstilimab aims to restore T-cell activity against tumors. It has been evaluated in over 900 patients to date and has demonstrated clinical activity with a favorable tolerability profile in several tumor types. Balstilimab is being studied both as a monotherapy and in combination with other agents (such as botensilimab) to expand its therapeutic impact. Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the botensilimab and balstilimab clinical programs, expected trial initiations, regulatory plans, and potential benefits of the combination therapy. These statements are subject to risks and uncertainties described in Agenus' most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Agenus cautions investors not to place undue reliance on these statements, which speak only as of the date of this announcement. The company undertakes no obligation to update or revise these statements, except as required by law.
CBC
2 days ago
- CBC
Medical professionals weigh in as Londoners react to secret dog study at St. Joseph's hospital
As animal-loving Londoners express "horror" at a local hospital's use of dogs in scientific studies, medical professionals say there are ethical ways to reduce harm and death in animal-based research. A story published Wednesday by the Investigative Journalism Bureau, in partnership with Postmedia, found that dogs are being used in a heart study at St. Joseph's Health Care's Lawson Research Institute. Researchers are secretly inducing three-hour heart attacks in dogs and puppies, the investigative report said, before euthanizing them and removing their hearts for further study. The hospital has kept the research under wraps, wheeling in the animals in blanket-covered crates and playing loud music to drown out the barking, according to the report. "I was absolutely horrified and I was really, really angry," said longtime Londoner Orreanna Douglas. "The sting of this shock is basically like the stun these poor, suffering dogs are getting. I'm livid that this is going on here. Douglas, whose children were born at St. Joseph's and who has been getting physiotherapy at the hospital for the last four months, said she cancelled her latest appointment at the hospital due to her frustrations. "I can't go back now, nor will I until the situation is rectified," she said. St. Joseph's has refused interview requests. In a statement to CBC News, officials confirmed that dogs, rodents, fruit flies and other large mammals are used in research. Other Londoners have taken to social media to express their outrage and non-profit organization Animal Justice Canada is planning a Saturday vigil for the dogs outside of the hospital. Meanwhile, medical experts have differing opinions on the use of animals in scientific study and the ethics that surround the practice. "[Animals] are needed because they're complex systems," said Pierre Verreault, the executive director of the Canadian Council of Animal Care (CCAC), which develops standards for the ethical use and care of animals in science. Different types of animals are used to try new medical treatments, ensure medical products are safe to sell, and teach veterinarians different procedures, Verreault said, adding that dogs are often used for regulatory testing purposes. Research projects must be approved by a panel before being granted funding, Verreault said, and part of that includes presenting a protocol to an animal care committee which conducts an ethical review. The core of animal research ethics is referred to as the Three Rs: Replacement, reduction and refinement. "Is there an alternative method? If yes, you shouldn't use an animal. Reduction is, 'Do you need to use that amount of animals to conduct research?" Verreault said. The principle, refinement, aims to minimize pain and distress by using pain medication if possible and giving the animal comfort. St. Joseph's officials have been on the defensive since the report came out. In a note sent to staff and volunteers on Thursday, obtained by CBC News, officials said they "acknowledge how difficult this story is" and that it "evokes strong feelings," but that hospital is "committed to ethical research at every stage of the discovery and innovation process." "The care, treatment and welfare of animals involved in Lawson research is taken extremely seriously and every possible step is taken to ensure their comfort and minimize suffering," the note to staff said. However, other experts say there are no ethical methods to animal testing. "There are [ethics] that are written on paper and there are ones that are actually practiced in a laboratory," said Charu Chandrasekera, executive director of the Canadian Centre for Alternatives to Animal Methods, who previously worked in a lab that studied heart failure using animals. "The three R's have become rather unjustified. They've become a box-ticking formality in a system more focused on paperwork than real accountability," she said. "Humans are not 60 kilogram mice, rats, guinea pigs, rabbits, cats, dogs or monkeys. We are not equivalent biologically…The differences are immutable," she said, adding that scientific facilities should look at alternatives to animal testing now that technology has developed. Alternatives exist, experts say "Justifying the use of animals because it has worked in the past at a time when new technologies weren't available is like praising the telegraph in the age of Zoom," Chandrasekera said. In a statement, St. Joseph's said the purpose of its dog research is to look at post-heart attack injury and healing, which cannot be done using other methods. "These techniques are essential for providing clinical teams with tools that permit proper diagnosis and treatment for heart attacks and heart failure, one of the leading causes of death in Canada," the statement said. Both experts say there are ways to reduce or rid animal testing in a scientific setting, and the technology is developing daily. Chandrasekera say there is a "toolbox" of alternatives, but recommends scientists who want to advance their research refer to already-published human studies that contain MRI and PET images. Verreault's suggestions for testing include developing cells to do research experiments, simulating experiments on chips, or reusing tissue from animals who were used in previous experiments. "Sometimes it can completely replace the animals in certain types of research, but sometimes it may only replace a certain part of it because an animal is like a human being. It's a very complex system that's still hard to replace," Verreault said.
